Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents

BACKGROUND: Abiraterone and enzalutamide are novel endocrine treatments that abrogate androgen receptor (AR) signalling in castration-resistant prostate cancer (CRPC). Here, we developed a circulating tumour cells (CTCs)-based assay to evaluate AR expression in real-time in CRPC and investigated nuc...

Descripción completa

Detalles Bibliográficos
Autores principales: Crespo, M, van Dalum, G, Ferraldeschi, R, Zafeiriou, Z, Sideris, S, Lorente, D, Bianchini, D, Rodrigues, D N, Riisnaes, R, Miranda, S, Figueiredo, I, Flohr, P, Nowakowska, K, de Bono, J S, Terstappen, L W M M, Attard, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385957/
https://www.ncbi.nlm.nih.gov/pubmed/25719830
http://dx.doi.org/10.1038/bjc.2015.63

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385957/
https://www.ncbi.nlm.nih.gov/pubmed/25719830
http://dx.doi.org/10.1038/bjc.2015.63

Ejemplares similares